<DOC>
	<DOCNO>NCT02976493</DOCNO>
	<brief_summary>BMS conduct regulatory postmarketing surveillance ( PMS ) evaluate safety elotuzumab clinical practice Japan .</brief_summary>
	<brief_title>Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>All patient relapse refractory multiple myeloma begin receive elotuzumab select site include surveillance study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>